Aquestive Q1 Misses, Anaphylm Launch Uncertain

What happened

Aquestive's first-quarter 2026 results showed continued revenue erosion and widening operating losses, with legacy Suboxone manufacturing declining and SG&A costs remaining elevated for a still-undefined Anaphylm launch. The business update failed to provide concrete metrics on commercial traction or FDA status, leaving the binary turnaround story in limbo. The balance sheet remains precariously levered with negative equity and high-cost debt, even as cash burn accelerates without a clear refinancing plan. Management's optimistic framing cannot mask the fundamental reality: the company is burning through cash faster than anticipated, and Anaphylm's uptake is proving elusive. This reaffirms our view that the market overprices a smooth approval and ramp, while understating the risk of a dilutive restructuring or outright failure.

Implication

Investors should reduce positions given Q1 confirmed persistent losses and no catalyst to de-risk the Anaphylm launch. The lack of a clear path to positive cash flows and the overhang of debt and royalties cap upside. Our base case of $7.00 appears optimistic; the bear case of $3.50 is more probable if Anaphylm uptake disappoints. We recommend taking profits on any remaining long positions and waiting for clearer evidence of commercial success.

Thesis delta

This report reinforces our existing bearish stance. The lack of positive news from the Q1 update and continued cash burn increase the likelihood of our bear case scenario. Our conviction in the POTENTIAL SELL rating increases, with downside bias.